Esther Rajavelu
Stock Analyst at UBS
(0.95)
# 3,953
Out of 5,141 analysts
23
Total ratings
54.55%
Success rate
-10.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $83.15 | -44.68% | 4 | Aug 12, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $20.19 | +58.49% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $336.19 | -36.05% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $22.72 | +221.30% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $11.23 | +870.61% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $34.29 | +2.07% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $172.19 | +32.41% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $63.59 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $23.39 | -44.42% | 1 | Nov 20, 2017 | |
| TXMD TherapeuticsMD | Initiates: Buy | $10 | $2.30 | +334.78% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $83.15
Upside: -44.68%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $20.19
Upside: +58.49%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $336.19
Upside: -36.05%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $22.72
Upside: +221.30%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $11.23
Upside: +870.61%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $34.29
Upside: +2.07%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $172.19
Upside: +32.41%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $63.59
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $23.39
Upside: -44.42%
TherapeuticsMD
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $2.30
Upside: +334.78%